Acute Coronary Syndrome

The addition of rivaroxaban to aspirin monotherapy reduces the risk of atherothrombotic events in patients who have experienced an acute coronary syndrome (ACS), but it can also increase those patients’ bleeding risk, according to a study published Feb. 28 in the Journal of the American Heart Association.

A systematic approach to transitioning heart attack patients from the hospital to outpatient care helped the Sanger Heart & Vascular Institute in Charlotte, North Carolina, drop its 30-day readmission and death rates while increasing the likelihood of patients making and keeping follow-up appointments.

ACC.19 will feature 36 late-breaking clinical trials and clinical research studies, starting with the Apple Heart Study’s findings on the ability of a smartwatch to help identify atrial fibrillation. That question is just one of many the conference will address, says ACC.19 Program Chair Andrew Kates, MD, professor of medicine and director of the cardiology fellowship program at Washington University School of Medicine in St. Louis. During a conversation with Cardiovascular Business, Kates predicted trial highlights and previewed some ACC.19 program innovations. 

Patients with coronary artery disease (CAD) enrolled in private insurance plans through Medicare Advantage (MA) are more likely to receive guideline-recommended medications for secondary prevention than those in fee-for-service Medicare, according to a new analysis in JAMA Cardiology. But that wasn't tied to improvements in blood pressure or cholesterol levels.

Transgender men and women might face an increased risk of cardiovascular ills like MI, stroke and venous thromboembolic events (VTEs) as a result of hormone replacement therapy—an often key aspect of the transitioning process for trans individuals.

An elevated heart rate upon hospital admission has been repeatedly linked to an increased risk of mortality for acute MI patients (AMI), making admission heart rate a key component of risk-stratification equations. But researchers recently found a patient’s heart rate at discharge was an even more powerful predictor of death over three years of follow-up.

High-risk strains of human papillomavirus (HPV)—ones that have been linked to anogenital and oral cancers—might also increase a woman’s risk for developing cardiovascular disease, research out of Seoul, South Korea, suggests.

Cardiovascular diagnoses such as chest pain and atherosclerotic heart disease are key drivers of outpatient payments, which accounted for almost 57 percent of hospitals’ net patient revenue in 2017, according to data compiled by Definitive Healthcare.

Just half of Americans know the five common heart attack symptoms—even when presented with the symptoms as “yes” or “no” answers—based on 2017 results from the National Health Interview Survey (NHIS).

A new study of young heart attack sufferers revealed a sobering, albeit unsurprising, finding: More than 90 percent had at least one modifiable risk factor. What’s equally concerning, according to the authors, is the prevalence of most of these risk factors increased over the decade-long study.

ProvideGx, a subsidiary of Premier, will begin its offerings with metoprolol, a beta-blocker that can treat blood pressure and angina and is commonly given to heart attack patients.

Biologic treatment favorably modifies coronary plaque characteristics for patients with severe psoriasis, suggests a study published Feb. 5 in Cardiovascular Research. The findings raise the possibility that the anti-inflammatory drugs can both treat psoriasis and reduce cardiovascular risk.